- Home
- KLTR vs ZURA Comparison
KLTR vs ZURA Comparison
Compare KLTR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLTR | ZURA |
|---|---|---|
| Founded | 2006 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.2M | 252.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | KLTR | ZURA |
|---|---|---|
| Price | $1.62 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.50 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 2.0M | 405.4K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $1.36 | $0.97 |
| 52 Week High | $2.82 | $4.68 |
Technical Indicators
Market Signals| Indicator | KLTR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 50.59 |
| Support Level | $1.40 | $3.51 |
| Resistance Level | $1.66 | $3.84 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 84.27 | 36.15 |
Price Performance
Historical ComparisonAbout KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.